Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 1, 2017

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2017

Conditions
Myeloma Multiple
Interventions
DRUG

Cyclophosphamide

Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.

DRUG

Lenalidomide

Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.

DRUG

Pembrolizumab

Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.

Trial Locations (4)

B15 2TH

Queen Elizabeth Hospital, Birmingham

NW1 2BU

University College Hospital, London

SE1 9RT

Guys and St Thomas NHS Foundation Trust, London

SO16 6YD

Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
collaborator

Myeloma UK

OTHER

collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

University of Leeds

OTHER